USD0.000æéå€ååŒÂ  (ET)
1.80BæäŸ¡ç·é¡
19.26çŽè¿12ã¶æPER
äž»èŠããŒã¿
79.650å§å€
80.380é«å€
205.18Kåºæ¥é«
19.26çŽè¿12ã¶æPER
7.42äºæ³PER
--çŽè¿12ã¶æé
åœ
0.91%売買å転ç
80.430忥çµå€
78.240å®å€
13.56M売買代é
æå€±é¡æ ªäŸ¡åçç
3.52PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
6.79%ç·è³ç£å©çç
99.50052é±é«å€
0.82åºæ¥é«æ¯ç%
-20.15MçŽå©ç
22.47Mæ ªåŒæ°
4.11381æ ªåœããå©çïŒEPSïŒ
0.45ããŒã¿å€
17.11%èªå·±è³æ¬å©çç
57.33052é±å®å€
2.66%æ¯ãå¹
51.78%ç²å©çç
1.80BæäŸ¡ç·é¡
-2.77ãªã¹ã¯ãªã¿ãŒã³
1.96%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
ANI Pharmaceuticals Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸããå»è¬åæ¥çã§ã®é äœã¯155äž10äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯109.29ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯å®å®æšç§»ãšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
ANI Pharmaceuticals Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
ANI Pharmaceuticals Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
ANI Pharmaceuticals Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
ANI Pharmaceuticals Inc
ANIP
8
ææšî
ææš
売ã(4)
äžç«(3)
è²·ã(0)
ç§»åå¹³å
売ã(5)
äžç«(0)
è²·ã(1)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ANI Pharmaceuticals Incã®äŒæ¥æ
å ±î
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
äŒæ¥ã³ãŒãANIP
äŒæ¥åANI Pharmaceuticals Inc
æé«çµå¶è²¬ä»»è
ãCEOãLalwani (Nikhil Suresh)
ãŠã§ããµã€ãhttps://www.anipharmaceuticals.com/
æ ªäž»çµ±èšî
ãããã質å
ANI Pharmaceuticals IncïŒANIPïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îANI Pharmaceuticals IncïŒANIPïŒã®çŸåšã®æ ªäŸ¡ã¯79.24ã§ãã
ANI Pharmaceuticals Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îANI Pharmaceuticals Incã®ãã£ãã«ãŒã·ã³ãã«ã¯ANIPã§ãã
ANI Pharmaceuticals Incã®52é±é«å€ã¯ãããã§ããïŒ
îANI Pharmaceuticals Incã®52é±é«å€ã¯99.50ã§ãã
ANI Pharmaceuticals Incã®52é±å®å€ã¯ãããã§ããïŒ
îANI Pharmaceuticals Incã®52é±å®å€ã¯57.33ã§ãã
ANI Pharmaceuticals Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îANI Pharmaceuticals Incã®æäŸ¡ç·é¡ã¯1.78Bã§ãã
ANI Pharmaceuticals Inc (ANIP) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãANI Pharmaceuticals IncïŒANIPïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯109.29ã§ãã
ANI Pharmaceuticals Inc (ANIP) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îANI Pharmaceuticals IncïŒANIPïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯3.50ã§ãã